NCT04163107 - Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

19

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

December 28, 2021

Study Completion Date

December 28, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

Hydroxychloroquine

All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

DRUG

Carfilzomib Injection

All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

DRUG

Dexamethasone

All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

Trial Locations (2)

Unknown

Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo

St. Olavs Hospital, Department of Hematology, Trondheim